Bachem Holding AGBCHMF 91 PB Ratio is 3.58 as of Jun. 25, 2026, which is 22% below its 10-year median of 4.59. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Bachem Holding AG ranks worse than 60.1% on this metric.
The historical rank and industry rank for Bachem Holding AG's PB Ratio or its related term are showing as below:
BCHMF'
s PB Ratio Range Over the Past 10 Years
Min: 2.51 Med: 4.59 Max: 24.65
Current: 3.49
During the past 13 years, Bachem Holding AG's highest PB Ratio was 24.65. The lowest was 2.51. And the median was 4.59.
BCHMF's PB Ratio is ranked worse than 60.1% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs BCHMF: 3.49
During the past 12 months, Bachem Holding AG's average Book Value Per Share Growth Rate was 4.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bachem Holding AG was 39.00% per year. The lowest was -4.00% per year. And the median was 2.70% per year.
Back to Basics: PB Ratio
Bachem Holding AG (OTCPK:BCHMF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bachem Holding AG PB Ratio Related Terms
Bachem Holding AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bachem Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bachem Holding AG (BCHMF) has a PB Ratio of 3.58 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bachem Holding AG and its competitors. This is 22% below median its historical median of 4.59. Over the past decade, Bachem Holding AG's PB Ratio has ranged from 2.51 to 24.65. According to the industry distribution chart, Bachem Holding AG ranks #741 out of 1233 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Bachem Holding AG's PB Ratio too high?
Bachem Holding AG's current PB Ratio of 3.58 is 22% below median its 10-year median of 4.59. Over the past 10 years, this metric has ranged from a low of 2.51 to a high of 24.65. The Biotechnology industry median PB Ratio is 2.80. Bachem Holding AG's value of 3.58 is 27.9% above this industry median. Based on the distribution chart, Bachem Holding AG ranks #741 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #741 out of 1233 companies for PB Ratio. This places Bachem Holding AG in the lower half of its industry. The industry median PB Ratio is 2.80. Bachem Holding AG's value of 3.58 is 27.9% above this benchmark. Historically, Bachem Holding AG's own PB Ratio has ranged from 2.51 to 24.65 over the past decade. While the company's 10-year median is 4.59 vs. the industry median of 2.80, Bachem Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current PB Ratio of 3.58 is 27.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bachem Holding AG and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current PB Ratio is 3.58, which is 22% below median its own 10-year median of 4.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.14, compared to a current price of $87.34 — trading 11% below its estimated fair value. The current PB Ratio is 3.58, which is 22% below median its 10-year median of 4.59 and 27.9% above the Biotechnology industry median of 2.80. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current PB Ratio is 3.58 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11% below its estimated GF Value™ of $98.14.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
PB Ratio: 3.58 (22% below median its 10-year median of 4.59)
GF Value™: $98.14 vs. price of $87.34 (11% below fair value)
Industry Position: 27.9% above the Biotechnology median (#741 of 1233)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
